Vistogard
(uridine triacetate)PreclinicalSmall molecule
Vistogard is one of 38 small molecule programs targeting Toxicity. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
37
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
1
Patents
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
223 competitors in Toxicity
#DrugCompanyPhaseTrials
1Cytotec
PfizerPhase 3
Erbitux
IImclone
Phase 3
Coly-Mycin M
PParkedale
Phase 3
Mucosta
OtsukaPhase 3
Sustiva
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Paracetamol
GSKPhase 3
Cysteine Hydrochloride
NovartisPreclinical
Dypirone
UUniversity of Sao Paulo General Hospital
Phase 3
Cellcept
NovartisPreclinical
Afinitor
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Sep 4, 2015
XURIDEN
NDA NDA208169
Dec 11, 2015
VISTOGARD
NDA NDA208159
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for uridine triacetate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- BBTG International Inc.
Patent Landscape[5]
Patent Cliff
Aug 17, 2027
Earliest patent expiration — generic entry possible after this date
Patent #Expires
7776838Aug 17, 2027